ReviewThe American journal of pathology1994
Prostate cancer progression. Implications of histopathology.
Review in The American journal of pathology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Novel insights in cell cycle dysregulation during prostate cancer progression.Endocrine-related cancer · 2021Review
- TGFβ-induced phosphorylation of Par6 promotes migration and invasion in prostate cancer cells.British journal of cancer · 2015Article
- Towards the prevention and management of prostatic diseases in Nigeria: a framework.The Malaysian journal of medical sciences : MJMS · 2011Article
- The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion.Journal of cellular physiology · 2010Review
- Genomewide scan for prostate cancer-aggressiveness loci.American journal of human genetics · 2000Article
- Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma.The American journal of pathology · 1996Article
- Expression of E-cadherin in primary and metastatic prostate cancer.The American journal of pathology · 1996Article
- The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression.Cancer metastasis reviews · 1995Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
This review examines selected areas of contemporary prostate cancer research in terms of the impact of prostatic cellular and histopathological heterogeneity. Prostate tumor progression is accompanied by dysregulation of multiple growth factor networks as well as disruption of normal patterns of cell-cell interactions. Molecular and cytogenetic studies demonstrate that prostate cancer results from the accumulation of several different genetic defects. No single event predominates, but modifications in tumor suppressor genes or functional elimination of the suppressor gene product are more common than activation of known oncogenes. Intratumor heterogeneity is also detectable at the genetic level. This further complicates efforts to correlate modifications at specific loci with progression or outcome. The development of new in vitro and in vivo systems for the study of human prostate cancer should increase our understanding of this complex disease. In each approach, knowledge of the histopathology of the normal and neoplastic prostate is essential.
Indexed as
Identifiers
7977655PMC1887423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.